Tirzepatide (GIP/GLP-1 receptor agonist) and survodutide/pemvidutide (GPCR/GLP-1 receptor agonist weekly once) have been shown to induce significant weight reduction in individuals with T2D and obesity.15–17 Recent studies have demonstrated the beneficial metabolic effects of tirzepatide on the liver by alleviating oxidative stress and inflammation through modulation of the lipid metabolism pathway.18 The studies show that tirzepatide could reduce key inflammatory markers, such as YKL-40, intracellular adhesion molecule 1, C-reactive protein, leptin and growth differentiation.19 The gene discussed is GLP1R; the disease is obesity disorder.